drugset
drugset / Trial / NCT01233921

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

NCT01233921 ↗

Completed 6 enrolled Martin, Paul National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant. PURPOSE: This randomized clinical trial studies palifermin in preventing chronic graft-versus-host disease in patients who have undergone donor stem cell transplant for hematologic cancer

Timeline

Start
2010-09
Primary completion
2012-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Palifermin Protein / enzyme biologic — Intravenous

Indications

Burkitt lymphoma Hodgkins lymphoma MALT lymphoma acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(15;17)(q24;q21) acute myeloid leukemia, t(16;16)(p13.1;q22) adult acute lymphoblastic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic eosinophilic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myelomonocytic leukemia chronic neutrophilic leukemia diffuse large B-cell lymphoma graft versus host disease hairy cell leukemia large-cell immunoblastic lymphoma leukemia, myeloid, accelerated-phase mantle cell lymphoma mycosis fungoides and variants myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable nodal marginal zone B-cell lymphoma plasma cell myeloma primary cutaneous T-cell non-Hodgkin lymphoma primary myelofibrosis splenic marginal zone lymphoma